Tapasree Banerji, Ph.D. (she/her)

Education and training

  • Degrees

    • Ph.D., 1986, University Of Calcutta

Publications

Selected publications

  • Bohlen, J.F.; Colin, M.C.; Das, D.;Rao Sripathy, S.; Sadowski, N.; Shim, G.; Kennedy, R.F.; Buchler, I.P.; Banerji, T.; Scanlan, T.S.; Mulkey, D.K.; Brady, J.M. (2023). Promyelinating drugs promote functional recovery in an autism spectrum disorder mouse model of Pitt-Hopkins syndrome. Brain, 146, 3331-3346.
  • Hartley, M.D.; Banerji, T.; Tagge, I.; Kirkemo, L.; Chaudhary, P.; Calkins, E.; Galipeau, D.; Shokat, M.; DeBell, M.; VanLeuven, S.; Marracci, G.; Pocius, E.; Banerji, T.; Ferrara, S.J.; Meinig, J.M.; Emery, B.; Bourdette, D.; Scanlan, T.S. (2019). Myelin repair stimulated by CNS-selective thyroid hormone action. JCI Insight, 4(8):e 126329.
  • Meinig, J.M.; Ferrara, S.J.; Banerji, T.; Banerji, T.; Sanford-Crane, H.S.; Bourdette, D.; Scanlan, T.S. (2019). Structure-activity relationships of CNS penetration by fatty acid amide hydrolase (FAAH) targeted thyromimetic prodrugs. ACS Med. Chem. Lett. 10(1), 111-116, Featured on Cover.
  • Meinig, J.M.; Ferrara, S.J.; Banerji, T.; Banerji, T.; Sanford-Crane, H.S.; Bourdette, D.; Scanlan, T.S. (2017). Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy. ACS Chemical Neuroscience, 8(11), 2468-2476.
  • Ferrara, S. J.; Meinig, J.M.; Placzek, A. T.; Banerji, T.; McTigue, P.; Hartley, M.D.; Sanford-Crane, H.S.; Banerji, T.; Bourdette, D.; Scanlan, T.S. (2017). Ester to Amide Rearrangement of Ethanolamine-derived Prodrugs of Sobetirome with increased Blood-Brain Barrier Penetration. Bioorganic & Medicinal Chemistry, 25, 2743-2753.
  • Hartley, M.D.; Kirkemo, L.L.; Banerji, T.; Scanlan, T.S. (2017). A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy. Endocrinology, 158(5), 1328-1338.